Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

PHASE4CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

April 29, 2024

Study Completion Date

April 29, 2024

Conditions
Advanced NSCLC
Interventions
GENETIC

Gene Profile explore

The tissue and blood sample for this genetic research will be obtained from the participants at baseline(disease progression after 1L Osimertinib). Paired tissue and whole blood sample should be collected per participant for genetics during the study.

Trial Locations (16)

100210

Research Site, Beijing

116023

Research Site, Dalian

150081

Research Site, Harbin

200032

Research Site, Shanghai

225300

Research Site, Taizhou

230001

Research Site, Hefei

230601

Research Site, Hefei

276826

Research Site, Rizhao

300060

Research Site, Tianjin

317000

Research Site, Linhai

350014

Research Site, Fuzhou

410013

Research Site, Changsha

450000

Research Site, Zhengzhou

471003

Research Site, Luoyang

528000

Research Site, Foshan

610014

Research Site, Chengdu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY